Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer

NCT01556191 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT01556191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01556191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2012
Completion date
June 17, 2020
Enrollment
379 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv lung cancer